Key facts
- It has raised $60K; the latest was Seed Round ($60K) in Oct 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for NearField Atomics
- ·The full record, as it builds
Funding rounds
No funding rounds for NearField Atomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NearField Atomics
Developer of an autonomous molecular design platform designed to accelerate drug and compound discovery. The company offers an evolutionary atomic-based design system backed by proprietary technology and deep intellectual property, enabling researchers and pharmaceutical developers to rapidly generate synthesis-ready molecular packages for advanced therapeutic and material innovations.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2020
- Employees
- 2
- Website
- nearfieldatomics.com/
- Ownership
- Privately Held (backing)
NearField Atomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NearField Atomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NearField Atomics in its N-PORT filings yet. We sweep new filings monthly.